Figure 2

Activity of MK-2206 following treatment with the combination of MK-2206 and trastuzumab in patients with human epidermal growth factor receptor 2-positive breast cancer or gastric cancer. (A) Time to progression for all patients enrolled who progressed during the trial and (B) best change in the size of target lesions from baseline, following treatment with the combination of MK-2206 and trastuzumab in patients with human epidermal growth factor receptor 2-positive breast cancer or gastric cancer. One patient achieved complete response and one patient had partial response; both patients withdrew from the study due to adverse events and are not included in (A). In (B), Patient 01719 had a 41% decrease in tumor size while on trial and achieved an overall 68% decrease in the size of target lesions while continuing to receive treatment after discontinuation of the study. (C) One patient with breast cancer who achieved complete response had an area of erythematous skin lesion on the operative site at baseline (left panel) that completely resolved after receiving two cycles of treatment at the 60 mg every other day (QOD) MK-2206 dose level (right panel). QW, every week.